Prospective, observational study in participants with active systemic lupus erythematosus (SLE) (including lupus nephritis) with inadequate response to glucocorticoids and at least 2 immunosuppressants (Benchmark-SLE)

未提供0 个研究点目标入组 12 人开始时间: 待定

适应症

试验速览

阶段: 不适用
状态: 招募中
入组人数: 12

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Observational

入排标准

年龄范围: No limit 至 No limit（—）
性别: All

入选标准

•Participants must have signed and dated an Institutional Review Board/ Independent Ethics Committee (IRB/IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines
•Participants must be >=16 years of age at the time of signing the ICF
•Meet the European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE)
•Have an inadequate response to glucocorticoids and >= 2 immunosuppressant therapies, one of which is a biologic therapy consistent with treatment guidelines, used for at least 3 months each. Eligibility is regardless of prior hydroxychloroquine or any anti-malarial treatment. Inadequate response is defined as a lack of response, insufficient response, or lack of sustained response after at least 3-month treatment with appropriate doses of a standard of care agent. Intolerance or contraindication may be considered as inadequate response provided it is documented and confirmed acceptable by the Adjudication Committee
•Have active disease at study entry when signing ICF, defined as:
•>= 1 British Isles Lupus Assessment Group Index (BILAG) A OR >= 1 BILAG B with history of SLE manifestations that would qualify for a BILAG A within the last 24 months, AND
•Positive autoantibodies (at least one) to confirm diagnosis of SLE: Antinuclear antibody >=1:160, anti-dsDNA, anti-Sm, anti-Ro (SSA), anti-La (SSB), or low complement proteins (C3 or C4)
•Participants with lupus nephritis (LN) meeting the study eligibility criteria must have had a renal biopsy per standard of care within 6 months (+- 30 days) prior to signing the ICF, indicating the presence of active Class III or IV LN (alone or in combination with Class V) according to the 2018 Revised International Society of Nephrology/Renal Pathology Society (ISN/RPS), with < 60% interstitial fibrosis and tubular atrophy < 60% global glomerulosclerosis

排除标准

•Pregnant women
•Participants enrolled in concurrent interventional clinical trials involving investigational therapies or any other clinical trial
•Participant is unwilling or unable to comply with routine clinical follow-up necessary for collection of study data

研究者

发起方

未提供

相似试验

招募中

1 期

A first study in healthy volunteers to examine the safety and tolerability of convalescent plasma given through the nose, as well as the duration of its presence in the noseHealthy volunteers

2025-525085-29-00Rode Kruis-Vlaanderen104

尚未招募

不适用

Effectiveness and Safety of Inebilizumab for IgG4-Related Disease in Real-World Clinical Setting in Japan: Protocol for a Long-Term Prospective Observational Study (4SigHT study)IgG4-Related Disease

jRCT1031250749100

尚未招募

不适用

A single-center prospective observational study to evaluate the safety and efficacy of sentinel lymph node navigation surgery (SNNS) for uterine malignanciesEarly-stage cervical cancer and early-stage endometrial cancer

jRCT1030260079196

已完成

1 期

A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole

2023-510472-31-00Janssen Cilag International18

招募中

不适用

A Multicenter, Prospective Observational Study to Evaluate the Efficacy and Safety of Mosunetuzumab Plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (W-JHS NHL04, SUNMOSTAR)

jRCT1071260043300